LivaNova (LIVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham maintained a Buy rating on the stock and has a ...

Barclays analyst Matt Miksic lowered the firm’s price target on LivaNova (LIVN) to $58 from $61 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook ...